Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma

被引：4

作者：

Schrenk, Karin G. ^{[1
]}

Weschenfelder, Wolfram ^{[2
]}

Spiegel, Christian ^{[2
]}

Agaimy, Abbas ^{[3
]}

Stoehr, Robert ^{[3
]}

Hartmann, Arndt ^{[3
]}

Gassler, Nikolaus ^{[4
]}

Drescher, Robert ^{[5
]}

Freesmeyer, Martin ^{[5
]}

Malouhi, Amer ^{[6
]}

Buerckenmeyer, Florian ^{[6
]}

Aschenbach, Rene ^{[6
]}

Teichgraeber, Ulf ^{[6
]}

Koegler, Christine ^{[7
]}

Vogt, Matthias ^{[8
]}

Hofmann, Gunther O. ^{[2
]}

Hochhaus, Andreas ^{[1
]}

机构：

[1] Univ Hosp Jena, Dept Hematol & Internal Oncol, Clin Internal Med 2, Klinikum 1, D-07747 Jena, Germany

[2] Univ Hosp Jena, Clin Trauma Hand & Reconstruct Surg, Jena, Germany

[3] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN CCC ER EMN, Inst Pathol, Erlangen, Germany

[4] Univ Hosp Jena, Inst Forens Med, Sect Pathol, Jena, Germany

[5] Univ Hosp Jena, Clin Nucl Med, Jena, Germany

[6] Univ Hosp Jena, Inst Diagnost & Intervent Radiol, Jena, Germany

[7] Malteser Hosp St Marien, Clin Gen & Visceral Surg, Erlangen, Germany

[8] Clin Medictr PartGmbB, Erlangen, Germany

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2023年 / 149卷 / 09期

关键词：

RET-fusion; Sarcoma; Selpercatinib; Targeted therapy; TRIM33; EFFICACY; CANCERS;

D O I：

10.1007/s00432-022-04496-y

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

With the increasing use of next-generation sequencing, highly effective targeted therapies have been emerging as treatment options for several cancer types. Recurrent gene-fusions have been recognized in sarcomas; however, options for targeted therapy remain scarce. Here, we describe a case of a sarcoma, associated with a RET::TRIM33-fusion gene with an exceptional response to a neoadjuvant therapy with the selective RET inhibitor selpercatinib. Resected tumor revealed subtotal histopathologic response. This is the first report of successful targeted therapy with selpercatinib in RET-fusion-associated sarcomas. As new targeted therapies are under development, similar treatment options may become available for sarcoma patients.

引用

页码：5493 / 5496

页数：4

共 50 条

[1] Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
Karin G. Schrenk
Wolfram Weschenfelder
Christian Spiegel
Abbas Agaimy
Robert Stöhr
Arndt Hartmann
Nikolaus Gaßler
Robert Drescher
Martin Freesmeyer
Amer Malouhi
Florian Bürckenmeyer
René Aschenbach
Ulf Teichgräber
Christine Kögler
Matthias Vogt
Gunther O. Hofmann
Andreas Hochhaus
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5493 - 5496
[2] Selpercatinib: First approved selective RET inhibitor
Oliveira, Larissa C. B.
Mulligan, Lois M.
CELL, 2023, 186 (08) : 1517 - 1517
[3] Novel RET Fusion RET-SEPTIN9 Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma
Mweempwa, Angela
Xu, Huiling
Vissers, Joseph H. A.
Tothill, Richard W.
Pattison, Andrew D.
Fellowes, Andrew P.
Thomas, David M.
Richardson, Gary
Hicks, Rodney J.
Grimmond, Sean M.
Fox, Stephen B.
Luen, Stephen J.
Desai, Jayesh
Solomon, Benjamin J.
JCO PRECISION ONCOLOGY, 2021, 5 : 1160 - 1165
[4] Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid
Kander, Elizabeth M.
Shah, Manisha H.
Zhou, Ye
Goyal, Ashima
Palmer, Joshua D.
Owen, Dwight H.
Shilo, Konstantin
Patel, Gopal
Raval, Raju R.
Gonzalez, Javier
Nguyen, Michele
Olek, Elizabeth
Kherani, Jennifer
Rothenberg, S. Michael
Konda, Bhavana
CLINICAL LUNG CANCER, 2021, 22 (03) : E442 - E445
[5] Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
Gouda, Mohamed A.
Subbiah, Vivek
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[6] Complete response to selpercatinib (LOXO-292), a highly selective RET inhibitor, in a patient with RET fusion-positive breast cancer
Takeda, Masayuki
Watanabe, Satomi
Rothenberg, S. Michael
Kherani, Jennifer
French, Pearl P.
Olek, Elizabeth
CANCER RESEARCH, 2020, 80 (16)
[7] Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer
Bhamidipati, Deepak
Yedururi, Sireesha
Huse, Jason
Chinapuvvula, Sri Veda
Wu, Jie
Subbiah, Vivek
JCO PRECISION ONCOLOGY, 2023, 7
[8] Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion-Positive Breast Cancer
Watanabe, Satomi
Takeda, Masayuki
Otani, Tomoyuki
Yoshida, Takeshi
Sakai, Kazuko
Olek, Elizabeth
Rothenberg, S. Michael
Kherani, Jennifer
French, Pearl P.
Nishio, Kazuto
Ito, Akihiko
Nakagawa, Kazuhiko
JCO PRECISION ONCOLOGY, 2021, 5 : 103 - 106
[9] Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report
Matrone, A.
Prete, A.
Sartini, S.
Elisei, R.
ANNALS OF ONCOLOGY, 2021, 32 (11) : 1447 - 1449
[10] Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
Yokota, Tomoya
CASE REPORTS IN ONCOLOGY, 2022, 15 (03): : 833 - 840

← 1 2 3 4 5 →